Seagen Inc.

Travis Biechele

William Arthur

Patrick J Burke

Rory Rohm

Robert Thurman

Django Sussman

Lori Westendorf

Andrew Waight

Chris Leiske

Jocelyn Leiske

The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.

Cysteine mutated antibodies for conjugation

The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.

Glypican 3 antibodies and conjugates thereof

This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.

Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors

This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.

Growing community of inventors

Seattle, WA, United States of America

Travis Biechele